Tohoku University Technology: Treatment for BRAF Mutant Cancer: T21-052
BRAFV600E mutation cancer treatment agent
The BRAFV600E mutation is observed in multiple cancer types and is associated with a poor prognosis compared to other molecular subtypes. In the treatment of BRAF-mutant colorectal cancer patients, targeted therapies have been developed and clinically introduced in 2020, including combination therapies of BRAF inhibitors with anti-EGFR antibody drugs, as well as a three-drug combination therapy of BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs. However, BRAF-mutant colorectal cancer still has a poor prognosis, and further effective treatment strategies are needed. Therefore, this invention proposes that retinoid receptor (particularly RARα or RXRα) agonists can enhance treatment effects or overcome acquired resistance in combination therapies of BRAF inhibitors with anti-EGFR antibody drugs or BRAF inhibitors, MEK inhibitors, and anti-EGFR antibody drugs, potentially serving as an effective treatment strategy for cancers with BRAFV600E, particularly colorectal cancer.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
